Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06242795 · ClinicalTrials.gov registry record · Phase 4

Hypertonic Saline in NCFB

A Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT06242795 is a Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06242795, a Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS. The study has two main questions: 1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis 2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS). Participants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening/enrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.

Conditions Studied

Bronchiectasis Non-cystic Fibrosis Bronchiectasis

Interventions

  • DRUG 7% Hypertonic Saline via nebulization

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-10-23
Est. Completion 2026-06
Phase Phase 4

Sponsor

University of North Carolina, Chapel Hill

1,109 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06242795

The ClinicalTrials.gov registry entry for NCT06242795 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (95% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Bronchiectasis appearing as the primary indexed condition, and to 1 intervention - of which 7% Hypertonic Saline via nebulization is the first listed.

NCT06242795 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06242795 about?

NCT06242795 is a clinical study titled "Hypertonic Saline in NCFB". The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a per...

What is the current status of trial NCT06242795?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-10-23. Estimated completion is 2026-06.

What conditions does trial NCT06242795 study?

This clinical trial studies the following conditions: Bronchiectasis, Non-cystic Fibrosis Bronchiectasis.

What interventions are being tested in trial NCT06242795?

The interventions under investigation include: 7% Hypertonic Saline via nebulization (DRUG).

Who is sponsoring clinical trial NCT06242795?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06242795 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bronchiectasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Bronchiectasis

All registered trials for this condition

Non-cystic Fibrosis Bronchiectasis

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.